Who Supplies Gabapentin to India from HUNGARY

To import finished pharmaceutical formulations containing Gabapentin (HS Code 30049081) into India, the importer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40 or 41, along with the necessary documentation, to the CDSCO. The registration process typically takes 6 to 12 months, depending on the completeness of the application and the regulatory review process. Gabapentin formulations must comply with the Drugs and Cosmetics Act, 1940, and the associated rules. The importer is also required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the import of pharmaceutical products.

Imported Gabapentin formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products.

In April 2025, the CDSCO mandated that all imported medicines, including finished pharmaceutical formulations containing Gabapentin, must obtain import registration and licenses to prevent the sale of unapproved or illegal medicines in the Indian market. This regulation aims to streamline the import process and ensure that all imported drugs meet the required quality, safety, and efficacy standards.

India imports finished Gabapentin formulations to meet the demand for specific dosage forms and branded products not available domestically. The market size for Gabapentin in India is substantial, with a growing prevalence of neuropathic disorders driving the need for effective treatments. Domestic manufacturers primarily produce generic versions, but imported branded formulations cater to a segment of the market seeking specific formulations or brand recognition.

The Basic Customs Duty (BCD) for HS Code 30049081 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the assessable value, which includes the CIF (Cost, Insurance, and Freight) value plus the BCD. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD. Additional cess or duties may apply depending on specific circumstances, but no anti-dumping duty is currently imposed on Gabapentin formulations. Exemption notifications may apply under certain conditions, but these are subject to change and should be verified with the latest government notifications.

India sources Gabapentin formulations from Hungary due to the availability of specific branded products and specialized dosage forms not produced domestically. Hungary's pharmaceutical industry is known for its high-quality standards and adherence to Good Manufacturing Practices (GMP). While other countries like China, Germany, and the United States also supply Gabapentin formulations, Hungary's competitive advantage lies in its unique product offerings and established trade relationships with India.

India imports Gabapentin formulations from Hungary to access specific branded products and specialized dosage forms not available domestically. Hungary's pharmaceutical industry is recognized for its high-quality standards and adherence to Good Manufacturing Practices (GMP), ensuring the safety and efficacy of the imported products. The importation of these formulations caters to a segment of the Indian market seeking specific treatments for neuropathic disorders.

Compared to other sources like China, Germany, and the United States, Hungary offers competitive pricing and high-quality Gabapentin formulations. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. Germany and the United States provide high-quality products but at higher prices. Hungary's unique advantage lies in its balance of quality and cost-effectiveness, making it an attractive source for Indian importers.

Potential risks for Indian importers include single-source dependency, currency fluctuations between the HUF and INR, regulatory changes in Hungary or India, quality incidents, and shipping disruptions. To mitigate these risks, importers should establish contingency plans, maintain buffer stocks, and stay informed about regulatory developments in both countries.

1. 1Dual-Sourcing: Consider sourcing Gabapentin formulations from multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate inventory levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence on Hungarian suppliers, including audits of manufacturing facilities and review of quality certifications.
5. 5Regulatory Compliance: Stay updated on regulatory changes in both India and Hungary to ensure continuous compliance with import requirements.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the appropriate application form to CDSCO for import registration.
3. 3Import Registration Certificate: Obtain the certificate from CDSCO upon approval.
4. 4No Objection Certificate (NOC): Secure an NOC from DGFT for the import of pharmaceutical products.